Suicide gene therapy for graft-versus-host disease.
In allogeneic hematopoietic stem cell transplantation, donor-derived T cells are key players for early immune reconstitution and efficient engraftment, as well as the graft-versus-leukemia and graft-versus-infection effects. However, a severe and quite common life-threatening complication is the development of graft-versus-host disease, during which the alloreactive donor T cells attack the host. Controlling graft-versus-host disease while preserving the benefits of graft-versus-leukemia still constitutes a challenge. A promising approach for the control of graft-versus-host disease is suicide gene therapy, which involves the ex vivo genetic modification of donor T cells with a suicide gene that allows for the selective elimination of the cells in vivo if graft-versus-host disease occurs. This article presents an overview of such approaches with special reference to lessons learned from previous clinical experiences, as well as a discussion of critical factors in suicide gene therapy.
Georgoudaki
Anna-Maria
AM
Karolinska University Hospital Huddinge, Stockholm, Sweden.
Sutlu
Tolga
T
Alici
Evren
E
D041722:Genes, Transgenic, Suicide; D015316:Genetic Therapy; D006086:Graft vs Host Disease / Q000235:genetics / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D013601:T-Lymphocytes / Q000276:immunology